Cambrex Corporation  

(Public, NYSE:CBM)   Watch this stock  
Find more results for CBM
13.16
+0.03 (0.23%)
May 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 13.03 - 13.27
52 week 6.67 - 14.33
Open 13.22
Vol / Avg. 115,779.00/146,956.00
Mkt cap 395.14M
P/E 5.96
Div/yield     -
EPS 2.21
Shares 30.03M
Beta 1.34
Inst. own 93%
May 20, 2013
Cambrex at UBS Global Healthcare Conference - 1:00PM EDT - Add to calendar
May 6, 2013
Q1 2013 Cambrex Earnings Release
May 3, 2013
Q1 2013 Cambrex Earnings Conference Call - Webcast
Apr 30, 2013
Cambrex at Needham Healthcare Conference - Webcast
Apr 25, 2013
Cambrex Annual Stockholders Meeting
Mar 11, 2013
Cambrex at EBD BIO-Europe Spring
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 15.26% 22.87%
Operating margin 21.54% 12.91%
EBITD margin - 20.87%
Return on average assets 11.39% 17.15%
Return on average equity 27.36% 47.97%
Employees 891 -
Carbon Disclosure Rating - -

Address

ONE MEADOWLANDS PLAZA
EAST RUTHERFORD, NJ 7073
United States - Map
+1-201-8043000 (Phone)
+1-201-8049852 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Cambrex Corporation (Cambrex) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics. The Company�s business is consisted of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. Its products include active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company supplies its products and services globally to generic pharmaceutical companies. The Company�s owns 51% stake in Zenara Pharma (Zenara), which focuses on the formulation of final dosage form products. The Company�s products are sold through a combination of direct sales and independent agents.

Officers and directors

Steven M. Klosk President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Gregory P. Sargen Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Paolo Russolo President of Cambrex Profarmaco Milano
Age: 68
Bio & Compensation  - Reuters
Shawn P. Cavanagh Chief Operating Officer, Executive Vice President
Age: 46
Bio & Compensation  - Reuters
William M. Haskel Chief Compliance Officer, Senior Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
James G. Farrell Vice President, Corporate Controller
Age: 46
Bio & Compensation  - Reuters
John R. Miller Non-Executive Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Shlomo Yanai Non-Executive Vice Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Rosina B. Dixon M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Kathryn Rudie Harrigan Independent Director
Age: 62
Bio & Compensation  - Reuters